This website and its content are not intended to provide professional or financial advice. The views expressed here are based solely on the writer’s opinion, research, and personal experience, and should not be taken as factual information. The author is not a financial advisor and lacks relevant certifications in that regard. We highly recommend consulting a qualified financial advisor before making any investment decisions, as the information presented on this site is general in nature and may not be tailored to individual needs or circumstances.
Biotechnology companies are responsible for preparing, testing, and researching drugs and advanced scientific products that can bring significant improvements in the healthcare field. The industry encompasses various fields, such as pharmaceuticals, medical devices, diagnostics, agricultural biotech, industrial biotech, and environmental biotech.
The products these companies prepare must go through state regulatory bodies before entering the market. This takes time; hence investors have to wait for a considerable period before they make money out of these stocks. That said, the return on investment in these companies is significant considering the latest market trends after Covid 19. The biotech market is predicted to grow at an annual rate of 13.9% from 2022 to 2030. Let’s discuss biotech stocks in detail and dig into the steps to purchase these stocks.
Contents
What Are Biotech Stocks?
Biotech stocks are stocks of companies that are engaged in the biotechnology industry. Biotechnology uses living organisms, cells, and biomolecules to develop products and processes that improve human health and the environment. Biotech companies use cutting-edge science and technology to develop new drugs, therapies, and medical treatments that have the potential to treat, cure, or prevent diseases.
Biotech companies are typically focused on research and development of new products, which can make them high-risk, high-reward investments. These stocks can experience significant volatility due to clinical trial results, regulatory approvals, and market competition. As a result, biotech stocks can attract investors seeking potentially large returns who are willing to take a high degree of risk.
TOP 5 Biotech Stocks
Knowing the best biotech stocks can be challenging due to the high-risk nature of the industry. However, evaluating a company’s pipeline is a good place to predict whether any biotech company is good to invest in. To be more effective, look for companies with a diverse portfolio of products in various stages of development. Let’s look at the five best biotech companies that possess maximum positives from an investor’s point of view.
1. ITeos Therapeutics Inc. Stock
ITeos Therapeutics Inc. is a clinical-stage biopharmaceutical company that focuses on developing cancer immunotherapies. The company’s lead product candidate is EO2401, a TIGIT antagonist antibody that is being evaluated in Phase 1/2 clinical trials for the treatment of advanced solid tumors.
ITeos also has a pipeline of additional product candidates targeting various immune checkpoints, including PD-1/LAG-3 and other immuno-oncology targets.
The launch of these two new product candidates is a significant event for ITeos, and their success in clinical trials and regulatory approval can significantly impact the company’s stock prices. Positive results from clinical trials and regulatory approval can increase the company’s stock price, while negative results can lead to a decrease in the stock price. So, as an investor, you should be aware of the risk to reward ratio of investing in ITeos.
ITeos Therapeutics Inc. went public on July 10, 2020, with an initial public offering (IPO) price of $19.00 per share. Since then, the stock price has fluctuated and has experienced significant changes.
2. Exelixis
Exelixis, founded in 1994, is another biotechnology company focusing on developing and commercializing small molecule therapies for cancer treatment. The company’s lead product is Cabometyx (cabozantinib), a drug used to treat patients with advanced renal and hepatocellular carcinoma.
Exelixis also has a pipeline of other product candidates in various stages of development, including potential treatments for prostate cancer, non-small cell lung cancer, and other cancers.
Exelixis went public in February 2000. At that time, the initial public offering (IPO) price was $14 per share. Since then, the stock price has fluctuated and may have experienced significant changes since the time of this writing. Exelixis is currently traded on the NASDAQ stock exchange under the ticker symbol EXEL. You can also invest in this stock through different stock brokers.
3. Regeneron Pharmaceuticals
Regeneron Pharmaceuticals focuses on the discovery, development, and commercialization of medicines for serious medical conditions. The company’s product portfolio includes treatments for eye, cardiovascular, allergic, inflammatory diseases, cancer, and rare genetic diseases.
Regeneron Pharmaceuticals has several products that have been successful and have contributed to the company’s growth. However, its best-performing product to date is EYLEA (aflibercept), a medication used to treat several eye diseases, including neovascular (wet) age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion.
The company also has a pipeline of product candidates in various stages of development, including potential treatments for asthma, atopic dermatitis, and COVID-19. Regeneron Pharmaceuticals went public on September 19, 1991, with an initial public offering (IPO) price of $12 per share. Regeneron Pharmaceuticals is headquartered in Tarrytown, New York, and is traded on the NASDAQ stock exchange under the ticker symbol REGN.
4. Beam Therapeutics Inc.
Beam Therapeutics Inc. is one of the fastest growing biotechnology companies that develops precision genetic medicines based on its proprietary base editing technology. The company’s platform allows for precise changes to the genetic code of cells, potentially enabling treatments for a wide range of diseases, including genetic disorders and cancer.
Beam’s lead product candidate is BEAM-101, an investigational treatment for sickle cell disease and beta-thalassemia, which is currently in Phase 1/2 clinical trials. The company also has a pipeline of other product candidates in various stages of development, including potential treatments for liver and eye diseases.
Beam Therapeutics Inc. went public on February 11, 2020. The company’s initial public offering (IPO) consisted of 10.6 million shares of common stock priced at $17 per share, raising approximately $180 million. Beam Therapeutics Inc. is headquartered in Cambridge, Massachusetts, and is traded on the NASDAQ stock exchange under the ticker symbol BEAM.
5. Twist Bioscience
Twist Bioscience is a biotechnology company that focuses on synthetic DNA and genomics. The company’s technology platform enables rapid, high-quality DNA synthesis at scale, which is crucial in developing synthetic biology, gene therapy, and precision medicine.
The company has continued to grow and expand its offerings since going public, including launching new products and entering partnerships with other biotechnology companies. As of February 2023, the market capitalization of Twist Bioscience is over $1.2 billion, making it one of the most valuable biotech companies on the market.
Investors and analysts are generally optimistic about the prospects of Twist Bioscience, as the company is well-positioned to take advantage of the growing demand for synthetic biology and gene editing technologies. However, as with any investment, there are risks involved, and potential investors should carefully consider the company’s financials, growth prospects, and competitive landscape before making any investment decisions.
Twist Bioscience is a publicly-traded company listed on the Nasdaq Global Market under the ticker symbol TWST. The company went public in October 2018, offering 5 million shares at a price of $14 per share. Since then, the stock has seen significant growth, reaching over $200 per share in February 2021.
Understanding the Biotech Stock Market
Before investing in Biotech Stocks, developing a firm understanding of the market is important. This will include in-depth research about the stock you are investing in and the risk-to-reward ratio of this industry’s stock.
1. Analyzing the Selected Biotech Stock
Analyzing a biotechnology stock can be a complex process that requires a deep understanding of the company’s technology, product pipeline, financials, management team, and competitive landscape. Biotech companies operate in a highly competitive and rapidly evolving industry, making it difficult to assess their potential.
It’s important to understand the company’s technology platform. Biotech companies are often founded on a novel technology that sets them apart from their competitors. You need to research the company’s technology platform, how it works, and its unique advantages over other technologies. Next, you should carefully evaluate the company’s product pipeline. Biotech companies often have a pipeline of products in various stages of development. Look at the company’s website, annual reports, and Securities and Exchange Commission (SEC) filings to understand what products the company is working on, the stage of development of each product, and the potential market size for each product.
It’s also important to analyze the financials of a biotech company. This includes revenue, expenses, cash flow, and profitability. Biotech companies often have high research and development (R&D) costs, so it’s important to look at the company’s R&D spending and assess whether it’s sustainable, given the company’s cash position and potential future revenue streams.
You should also understand the company’s competitive landscape. Biotech companies operate in a highly competitive industry. It’s important to understand who the company’s competitors are, what products they are working on, and what advantages they may have over the company you are analyzing.
2. Risks & Rewards Involved
Purchasing biotech stocks can be both risky and rewarding. The risks include the potential for clinical trial failures, regulatory hurdles, and high levels of competition. The rewards can consist of substantial gains if a drug candidate is approved or a larger player acquires the company. Biotech stocks can be particularly volatile, with large price swings in response to news and events. It’s important to research, diversify your portfolio, and only invest money you can afford to lose.
Key Factors To Consider When Choosing Biotech Stocks
Investing in a biotech company can be complex and requires careful consideration of several factors. Here are some major factors to consider when investing in any biotech company.
- The major thing to consider is the technology and innovation of the company. Assess the company’s pipeline of products in various stages of development, the potential market size for each product, and the innovation behind them.
- Approval from major regulatory bodies is another factor before investing in biotech companies. The government highly regulates biotech companies’ products and technologies, and the approval process can be long and expensive. This is why returns provided by these companies are mostly long term.
- The quality of a company’s management team is often an important factor in its success. Analyze the experience and track record of the CEO, CFO, and other key executives, and assess their ability to navigate the regulatory and competitive landscape.
- The next important thing to consider is the company’s financials. You must analyze the financial history and the market share of the company. It is also important to analyze revenue, expenses, cash flow, and profitability.
Overall, investing in a biotech company requires a thorough analysis of the company’s technology, regulatory and approval process, management team, financials, intellectual property, and competition.
Where Can You Trade Biotech Stocks?
While you may seem interested in investing in tech stock, the complicated process can stop you from making a move. The reason people do not invest in tech stocks is that they think it’s a challenging and complicated task. They’ll have to find a broker who makes them go through a long and tiring sign-up process.
However, online brokers such as eToro, allow you to invest in tech stocks without going through a hassle. It focuses on streamlining the investor experience. As a result, the platform is seeing substantial growth in its popularity.
Since it has the utmost priority of providing a smooth opportunity to invest in tech stocks, you won’t have to go through a long and daunting registration process. Here is an overview of the simple procedure you should follow when opening an account.
Biotech stocks can be purchased through various channels, including online brokers, traditional brokerages, and financial institutions. Investing in biotech stocks might seem appealing, but the complex process can deter you from taking action. Many people avoid investing in biotech stocks because they perceive it as a difficult and intricate task that requires finding a broker and going through a time-consuming and tiresome sign-up process. However, this is not the case when you invest through online brokers such as eToro, IG, E-trade, etc.
These online brokers offer a hassle-free option to invest in biotech stocks. They focus on simplifying the investment process, resulting in a significant increase in popularity. Let’s take a look at the process of trading biotech stocks through eToro.
Step 1: Open an Account
You can go to the main page and click on ‘create account’ to fill out the main application form. It will require you to fill in only the basic information, which only takes a couple of minutes.
To initiate the account creation process, navigate to the platform’s homepage and select the “Create Account” button. Once prompted, complete the primary application form, which requires basic information and can be accomplished in a matter of minutes.
Step 2: Upload ID
After completing the first step, you have to upload your identification documents to comply with the KYC and AML regulations. eToro will verify the documents and open your account to trade on the stock market. Here are the documents that you need to submit for verification:
The next step is to submit your identification documents to adhere to the KYC (Know Your Customer) and AML (Anti-Money Laundering) regulations. The eToro team will then undertake the verification process and proceed to open your account, allowing you to commence trading on the stock market. The following documents are mandatory to facilitate this verification process:
- Utility bill
- Driver’s license or a valid passport
- Bank account statement
Step 3: Make a Deposit
After creating your account, you can start trading stocks. But before that, you will need to make a deposit using your PayPal account, debit/credit card, or wire bank transfer.
Once your account is set up, you need to deposit funds to your account to start investing. To do this, you can use various funding channels, including PayPal, debit/credit card, or wire transfer.
Step 4: Find the right stock for you
On the eToro platform, you can see a wide range of stocks that you can purchase for the long term. The platform allows you to trade a stake with a single click, with the minimum amount being $10.
You can also take advantage of the search bar and look for stocks to invest in. After finalizing the shares you want to trade, you can click on the Trade option to make a bid. There is even an option stop-loss option that comes in handy when you want to save your investment.
After depositing the necessary funds, you must search for your desired stock and purchase them. eToro offers an advanced search filter and an easy-to-use interface, allowing you to search for the stock you want to invest in.
Conclusion
Biotech stocks are stocks of companies engaged in the biotechnology industry. These stocks are generally referred to as high-risk, high-reward investments considering the risks involved regarding the approval of products. Investors should look for companies with a diverse product portfolio, and pipeline and evaluate the risk-to-reward ratio before investing. The easiest way to invest in these companies is through online brokers. These brokers offer a hassle free user experience for investing in biotech stocks.
FAQs
Biotech stocks are stocks of companies engaged in the biotechnology industry. These companies use living organisms, cells, and biomolecules to develop products and processes that improve human health and the environment, such as new drugs, therapies, and medical treatments.
Biotech stocks are high-risk investments because these companies are typically focused on research and development of new products. Their success depends on factors like clinical trial results, regulatory approvals, and market competition, which can lead to significant volatility in their stock prices.
To identify promising biotech stocks, evaluate the company’s pipeline and look for companies with a diverse portfolio of products in various stages of development. This can provide a better indication of the company’s potential for success.
The biotech market is predicted to grow at an annual rate of 13.9% from 2022 to 2030, driven by advancements in healthcare and technology, as well as increasing demand for innovative treatments and therapies.
Investors may have to wait for a considerable period before making money from biotech stocks, as the products developed by these companies must go through state regulatory bodies before entering the market. The time required for approval can vary depending on factors like the complexity of the product and the regulatory process.
While identifying the best biotech stocks can be challenging due to the high-risk nature of the industry, investors can evaluate companies with a diverse portfolio of products in various stages of development. The article provides a list of five such companies, but the specifics have been omitted in this FAQ.
StockHax strives to provide unbiased and reliable information on cryptocurrency, finance, trading, and stocks. However, we cannot provide financial advice and urge users to do their own research and due diligence.
Read More